AARTIPHARM

What Aarti Pharmalabs promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 17 tracked 2 delivered 2 missed 13 open
  • Project Commissioning delayed said Q3 FY25 Promised: Commissioned in Q1 FY26 Q1 FY27: Delayed again. New target is Q2 FY27: 'Both phases of Atali Block 1 with 440 kL reactor capacity will become fully operational in Q2 FY '27.'
  • CDMO Revenue Growth delivered said Q4 FY25 Promised: 30% to 40% YoY Q4 FY26: Achieved 32% YoY growth for FY26 (₹276 crores vs ₹209 crores in FY25).
  • EBITDA Growth missed said Q4 FY25 Promised: 12% to 15% YoY Q4 FY26: FY26 EBITDA declined 5.14% YoY to ₹406 crores vs ₹428 crores in FY25.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 17 tracked commitments for Aarti Pharmalabs — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens